Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N, et al. Radiotherapy and theranostics: a lancet oncology commission. Lancet Oncol. 2024;25:e545–80..I.
International Atomic Energy Agency. Trends in Radiopharmaceuticals (ISTR-2019), Proceedings Series - International Atomic Energy Agency, IAEA, Vienna. 2020.
Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: a review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025;52:2685–709.
International Atomic Energy Agency. Comparative Evaluation of Therapeutic Radiopharmaceuticals, Technical Reports Series No. 458, IAEA, Vienna. 2007.
Sartor O, Baghian A. Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts. Front Med (Lausanne). 2022;9:1060922.
FDA Approves Lutathera for GEP NET Therapy. J Nucl Med. 2018;59:9 N.
FDA Approves Pluvicto. Locametz for metastatic Castration-Resistant prostate Cancer. J Nucl Med. 2022;63:13 N.
International Atomic Energy Agency. Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours, IAEA Human Health Series No. 20, IAEA, Vienna. 2013.
Siripongsatian D, de Lussanet QG, Anton Verburg F, Brabander T. How to design a theranostic trial? Endocr Oncol. 2024;4:e230045.
PubMed PubMed Central Google Scholar
INTERNATIONAL ATOMIC ENERGY AGENCY. Quality control in the production of radiopharmaceuticals, IAEA-TECDOC-1856. Vienna: IAEA; 2018.
International Atomic Energy Agency. A Model to Assess Staffing Needs in Nuclear Medicine, IAEA Human Health Eeports No. 19, IAEA, Vienna. 2022.
Momodu JI, Carvajal C, Pryma DA, Anie HA, Michalski JM, Yom SS, et al. The lancet oncology commission: radiotherapy & theranostic services in lmics: minding & mending the gaps. Int J Radiat Oncol Biol Phys. 2024;120:931–5.
Choudhury PS, Gupta M. Theranostics in india: a particularly exquisite concept or an experimental tool. Nucl Med Mol Imaging. 2019;53:92–5.
Article PubMed PubMed Central Google Scholar
Bashir H, Numair Younis M, Rehan Gul M. Nuclear medicine theranostics: perspective from Pakistan. Nucl Med Mol Imaging. 2019;53:38–41.
Article PubMed PubMed Central Google Scholar
Ferdousi Begum SM, Nisa L, Sarker AK. Theranostics in bangladesh: current status, challenges, and future perspective. Nucl Med Mol Imaging. 2019;53:102–7.
Article PubMed PubMed Central Google Scholar
Al-Ibraheem A. Theranostics in developing countries: addressing challenges and potentials from training to practice. World J Nucl Med. 2023;22:171–3.
Article PubMed PubMed Central Google Scholar
Lee DS, Lee YS, Lee JS, Suh MS. Promotion of nuclear medicine-related sciences in developing countries. Nucl Med Mol Imaging. 2019;53:73–82.
Article PubMed PubMed Central Google Scholar
Jain U, Rahim F, Jain B, Komanduri A, Arkalgud A, Sabet CJ, et al. Cancer burden across the South Asian association for regional Cooperation in 2022. BMJ Oncol. 2024;3:e000466.
Article PubMed PubMed Central Google Scholar
INTERNATIONAL ATOMIC ENERGY AGENCY. Training curriculum for nuclear medicine physicians, IAEA-TECDOC-1883. Vienna: IAEA; 2019.
Singh B, Sahani G, Prasad V, Watts A, Kumar R. India’s growing nuclear medicine infrastructure and emergence of radiotheranostics in Cancer care: associated challenges and the opportunities to collaborate. Indian J Nucl Med. 2023;38:201–7.
Article PubMed PubMed Central Google Scholar
Fatima S, Paracha YR. Transforming Cancer care through capacity Building of theranostic facilities in Pakistan– A success story of IAEA-Pakistan collaboration. Int J Cancer. 2024;155:4–121.
https://britatom.gov.in/en (last accessed on 9/3/2025).
Roohi S, Rizvi SK, Naqvi SAR. 177Lu-DOTATATE peptide receptor radionuclide therapy: indigenously developed freeze dried cold kit and biological response in In-Vitro and In-Vivo models. Dose-response. 2021;19:1559325821990147.
Article PubMed PubMed Central Google Scholar
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate Cancer patients. Theranostics. 2020;10:9364–77.
Article PubMed PubMed Central Google Scholar
Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934–46.
Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81–91.
Yadav MP, Ballal S, Martin M, Roesch F, Satapathy S, Moon ES, et al. Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment. Eur J Nucl Med Mol Imaging. 2024;51:805–19.
Rathore Y, Lakhanpal T, Chakraborty S, Chakravarty R, Mittal BR, Irrinki RNS, et al. Targeting breast Cancer using 177 Lu-Labeled trastuzumab and trastuzumab fragment: first-in-Human clinical experience. Clin Nucl Med. 2024;49:e258–65.
Shukla J, Goyal A, Chhabra A, Rathore Y, Bansal K, Pandey S, et al. Cold kit for Rhenium-188 microspheres based selective intra-arterial therapy (SIRT): preparation, characterization and feasibility study. Appl Radiat Isot. 2022;190:110423.
Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, et al. Guiding principles on the education and practice of theranostics. Eur J Nucl Med Mol Imaging. 2024;51:2320–31.
Article PubMed PubMed Central Google Scholar
https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=8S (last accessed on 9/3/2025).
Susan B, Crystal B, Sarah F, Anna MM, Chelsea W, Razi M, et al. Theranostic differences between the united States and the rest of the world. J Nucl Med. 2020;61:s13050.
Agency IAE. IMAGINE—IAEA Medical Imaging and Nuclear Medicine Global Resources DatabaseAccessed June 25, 2023, at:https://humanhealth.iaea.org/HHW/DBStatistics/IMAGINE.htm.
Cutler CS, Bailey E, Kumar V, Schwarz SW, Bom H-S, Hatazawa J, et al. Global issues of radiopharmaceutical access and availability: a nuclear medicine global initiative project. J Nucl Med. 2021;62:422–30.
Article PubMed PubMed Central Google Scholar
Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res. 2024;29:26.
Article PubMed PubMed Central Google Scholar
Sathekge M, Morgenstern A. Advances in targeted alpha therapy of cancer. Eur J Nucl Med Mol Imaging. 2024;51:1205–6.
Meher BR. Inclusion of radiopharmaceuticals in the Indian pharmacopeia: a step forward. Indian J Nucl Med. 2020;35:1–3.
Annex 2. International atomic energy agency and world health organization guideline on good manufacturing practices for radiopharmaceutical products. WHO Tech Rep Ser. 2020;1025:93–108.
Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale Preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6:8.
Article PubMed PubMed Central Google Scholar
Choudhury PS, Gupta M. In: The evolution of radionanotargeting towards clinical precision oncology: a festschrift in honor of kalevi kairemo. Jekunen A., editor. Bentham Science Publishers; 2022. Precision oncology through radiating bullets: what All we have conquered and what All we have to; pp. 246–254.
Francis RJ, Bailey DL, Hofman MS, Scott AM. The Australasian radiopharmaceutical trials network (ARTnet)—clinical trials, evidence and opportunity. J Nucl Med. 2021;62:755–56.
Comments (0)